Novel molecular targets in hepatocellular carcinoma

doi:10.5306/wjco.v11.i8.589

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6153)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

477

WORD

223

HTML

3393

Tables (1-3)

271

Sum=4364

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

703

Download

1086

Sum=1789

Aug 24, 2020 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Aug 24, 2020; 11(8): 589-605
Published online Aug 24, 2020. doi: 10.5306/wjco.v11.i8.589

Table 3 Clinical study of combined molecular targeted therapy based on sorafenib treatment for hepatocellular carcinoma

Drug + Sorafenib	Phase	Ref./ClinicalTrials.gov identifier
VEGF inhibitors
Bevacizumab	I/II	NCT00867321
Lenvatinib	I/II (HCC)	NCT01271504
mTOR inhibitor
Everolimus (RAD001)	II	NCT01005199
	I/II	[154]
Temsirolimus	I/II	NCT01335074, NCT01687673, NCT01008917
HDAC inhibitors
Resminostat	II (Advanced HCC)	NCT00943449
Panobinostat	I (HCC)	NCT00823290
Anti-GPC3 antibody
GC33	I	NCT00976170
MEK1 inhibitor
Selumetinib (AZD6244)	I/II	NCT01029418
HGFR inhibitor
Tivantinib (ARQ197)	I	NCT00827177
TNF-α secretion inhibitor
Lenalidomide	I	NCT01348503
TRAIL receptor 1 antibody
Mapatumumab	I/II	NCT00712855, NCT01258608

HGFR: Hepatocyte growth factor receptor; TNF-α: Tumour necrosis factor-α; TRAIL: Anti-TNF-related apoptosis-inducing ligand; HCC: Hepatocellular carcinoma; VEGF: Vascular endothelial growth factor; mTOR: Mammalian target of rapamycin.

Citation: Chow AKM, Yau SWL, Ng L. Novel molecular targets in hepatocellular carcinoma. World J Clin Oncol 2020; 11(8): 589-605
URL: https://www.wjgnet.com/2218-4333/full/v11/i8/589.htm
DOI: https://dx.doi.org/10.5306/wjco.v11.i8.589